Aurinia Pharmaceuticals (AUPH) Expected to Announce Quarterly Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is expected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.21 per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Aurinia Pharmaceuticals Trading Up 3.0%

NASDAQ AUPH opened at $14.83 on Tuesday. The company has a market cap of $1.96 billion, a PE ratio of 26.48 and a beta of 1.50. The company has a current ratio of 5.76, a quick ratio of 5.17 and a debt-to-equity ratio of 0.15. Aurinia Pharmaceuticals has a 12 month low of $6.55 and a 12 month high of $16.54. The stock has a 50 day moving average of $15.10 and a 200-day moving average of $13.85.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership raised its stake in Aurinia Pharmaceuticals by 213.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,374,021 shares of the biotechnology company’s stock worth $37,283,000 after purchasing an additional 2,297,903 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Aurinia Pharmaceuticals by 1,272.5% during the third quarter. Marshall Wace LLP now owns 1,483,132 shares of the biotechnology company’s stock worth $16,389,000 after purchasing an additional 1,375,072 shares during the period. Kotler Kevin acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $19,536,000. Two Sigma Investments LP boosted its stake in shares of Aurinia Pharmaceuticals by 728.6% in the third quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company’s stock valued at $14,819,000 after buying an additional 1,179,219 shares during the period. Finally, Man Group plc boosted its stake in shares of Aurinia Pharmaceuticals by 368.9% in the fourth quarter. Man Group plc now owns 852,671 shares of the biotechnology company’s stock valued at $13,600,000 after buying an additional 670,812 shares during the period. Institutional investors own 36.83% of the company’s stock.

Wall Street Analysts Forecast Growth

AUPH has been the subject of a number of recent analyst reports. Bloom Burton cut shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, January 21st. Leerink Partners cut Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and lifted their price target for the stock from $15.00 to $16.00 in a report on Wednesday, December 3rd. Royal Bank Of Canada reissued a “sector perform” rating and set a $15.00 price target (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 5th. Finally, Jefferies Financial Group raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the company from $10.00 to $21.00 in a research report on Friday, November 7th. Two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $17.25.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.